Kardiolytics’ VCAST technology receives new U.S. patent for autonomous segmentation using artificial intelligence for vascular disease diagnosis
Kardiolytics Inc., a subsidiary of Medicalgorithmics S.A., a company listed on the Warsaw Stock Exchange, has announced that it has been granted a new U.S. patent, Patent No. 11626211, for its VCAST technology used to diagnose vascular diseases. The patent concerns an autonomous method for modelling blood vessels and blood flow using a CT angiography scan.